Genetic Testing

Pre-implantation Genetic Diagnosis and Screening

HQA Fertility Testing

Pre-implantation Genetic Diagnosis (PGD)

We work with HQA Fertility Centers to offer PGD as an option to couples who are at risk of having a child with an inherited disorder.
PGD is a laboratory procedure performed in conjunction with in vitro fertilization (IVF) to help detect genetic diseases. Families affected by almost any inherited disease can reduce the risk their embryos will suffer that genetic disorder by working with our team. Even families in search of a bone marrow donor may be able to use PGD to bring a child into the world by providing matching stem cells. We at Genesis Genetics are the pioneers of this type of testing, and are globally recognized for our ability to test for some of the rarest genetic conditions.

The Process

We work with HQA Fertility Centers to offer PGD as an option. Once we receive your cheek swab samples and DNA test results, our experts build a probe specifically designed for your family. When the probe is complete, the biopsied cells are analyzed to determine embryos that have inherited the disease and those embryos that are free from the disease. These results are then provided to your HQA Fertility Center.

Many IVF centers offer PGD as part of their services; however embryo biopsy is a highly skilled procedure. That is why it is best to use a center that has experience with PGD to achieve the best outcomes. The level of communication and collaboration between the IVF team and the PGD team is highly important to the process. The IVF center may be hundreds of miles from the PGD reference laboratory. Such distance requires transportation of the cell(s) removed from the embryos growing in the incubator at the IVF center.

HQA Fertility Centers recognizes Genesis Genetics as a leader in PGD testing, and our partnership ensures the highest level of achievement.


Pre-implantation Genetic Screening (PGS)

Pre-Implantation Genetic Screening (PGS), is an IVF procedure designed to examine your embryos for chromosomal abnormalities. An embryo biopsy is taken either at day 3 or day 5 and all 24 chromosomes are examined—the 22 non-sex chromosomes plus the two sex chromosomes (X & Y) in time for your embryo transfer. Chromosomal abnormalities can result in aneuploidy (embryos having the wrong number of chromosomes – i.e. extra copy of chromosome 21 also known as Downs Syndrome), translocations (chromosomes incorrectly rearranged), or other chromosome alterations that may be clinically significant. PGS aims at improving pregnancy and live birth rates by screening your embryos for chromosomal abnormalities.
Screening can potentially benefit those who present with the majority of IVF indications. Particularly advanced maternal age couples and families who have had recurrent pregnancy losses both naturally and through IVF. A declining live birth rate is an increasing problem for families who choose to have children later in life and is strongly associated with late maternal age embryos showing greater levels of chromosomal abnormalities. Without PGS, embryos are chosen based only on their visual quality and morphology, which cannot distinguish chromosomally normal embryos from abnormal embryos. In IVF cycles that incorporate PGS, embryos are assessed by their chromosome content and are more likely to result in a pregnancy that is carried to full term.